
Wolters Kluwer releases new enhancements to Enablon Vision Platform
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
PRESS RELEASE
Wolters Kluwer releases new enhancements to Enablon Vision Platform
New innovations further solidify solution’s position as one of the most comprehensive,
user- friendly, integrated risk management software platforms on the market
Amsterdam – October 16, 2023 – Wolters Kluwer has launched several upgrades to its Enablon Vision Platform, bringing new functionality, automation, dashboards, and data visibility to operations, environmental, and safety teams.
The Enablon Vision Platform helps users lay the foundation for integrated risk management, by integrating, automating, and streamlining governance, risk, compliance, health and safety, environment and sustainability, business continuity, and internal audit practices across the organization. The platform provides a single source of truth for integrated risk management, and empowers users and executives to make better, more informed decisions. From supporting field staff in achieving an incident-free work environment, to simplifying environmental data collection, industry-leading enterprises use the platform to harmonize their risk approach and drive continuous improvement – from the plant floor to the executive suite.
Today’s announcement marks the second occasion this year that Wolters Kluwer has launched new innovations to Version 9 2023 of the Enablon Vision Platform, which was introduced in April 2023.
Notable additions included in today’s Enablon Vision Platform Version 9 2023 SP2 release include:
- New features to enhance Control of Work safety processes, like start-work checklists, where users can design checklists for their work permits. These checklists, which were previously managed outside the platform, are now fully integrated into the permit-to-work workflow, allowing users to implement changes more quickly and reduce unnecessary project delays.
- New features that enhance Environmental, Health, Safety, and Quality (EHSQ) processes, including smart cards for waste management, and improvements to the way users can input, resend and improve compliance related to safety data sheets, which help ensure that hazardous chemicals are appropriately handled.
- New global usability and process safety management improvements, including the introduction of safety manager dashboards that provide a snapshot of past and current site, region, or business safety issues, allowing users to make smart, agile decisions.
- Enhanced integration between Incident Management and IncidentXP, which helps users reduce repeat incidents, by making it easier to quickly conduct root cause analyses.
- Enhanced usability and performance improvements for mobility, including the ability to add media files, such as photos and videos, to event records in the Enablon Go mobile app, and a streamlined experience for users who need to access and manage data for multiple sites.
- Enhanced accessibility, including keyboard navigation and user interface compatibility with assistive technologies.
Rob Davis, Vice President of Product Management, Wolters Kluwer Enablon, said:
“The new Enablon Vision Platform functionality we're releasing today is proof of Wolters Kluwer's commitment to continual investment in innovations that ensure our single, cohesive, and user-friendly platform remains the best integrated risk solution on the market.”
Enablon, part of Wolters Kluwer’s Corporate Performance & ESG (CP & ESG) division, is the world’s leading provider of integrated software solutions for EHS, Environmental, Social, and Governance (ESG), Operational Excellence, and Governance, Risk and Compliance (GRC). The division helps create a better world by making organizations responsible, productive, and safe through innovative technology. Hundreds of industry-leading enterprises and millions of users, worldwide, rely on Enablon solutions to minimize risks, increase worker safety, prevent incidents from happening, achieve regulatory compliance, and reduce environmental impact.
# # #
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
Media Contact
Paul Lyon
Senior Director, External Communications
Wolters Kluwer
Mobile: +44 7765 391 824
Paul.Lyon@wolterskluwer.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates6.12.2023 12:38:48 CET | Press release
STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October - November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the company's orthobiologic franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million. A complete financial statement for the fourth quarter will be presented in OssDsign’s year-end report for 2023, to be published on February 6, 2024. "OssDsign continues its strong growth journey, and we are confident that the company's new strategic direction to fully focus the business on its high-margin orthobiologic franchis
Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar6.12.2023 12:38:48 CET | Pressemelding
STOCKHOLM, SVERIGE 6 december 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign bedömer att intäkterna för det fjärde kvartalet 2023 kommer överträffa marknadens förväntningar. De preliminära totala intäkterna för perioden oktober – november uppgår till 25,2 MSEK, främst till följd av en fortsatt stark marknadsutveckling för bolagets ortobiologiprodukter och ett antal större ordrar från ett stort sjukhusnätverk. Enligt preliminära och oreviderade försäljningsdata för perioden oktober – november 2023 uppnåddes intäkter om 18,8 miljoner kronor för OssDsign Catalyst, medan intäkterna för OssDsign Cranial uppgick till 6,4 miljoner kronor. En fullständig finansiell rapport för det fjärde kvartalet kommer att presenteras i OssDsigns bokslutskommuniké för 2023, som publiceras den 6 februari 2024. ”OssDsign fortsätter sin starka tillväxtresa och vi är övertygade om att bolagets nya strategiska inriktning för att fullt fokusera verksamheten på sina o
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.simm@tallink.ee
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi